Aβ, tau and ApoE4 in Alzheimer's disease: the axonal connection

Trends in Molecular Medicine

Volumn 13, Issue 4, 2007, Pages 135-142

  Adalbert, Robert ^a   Gilley, Jonathan ^a   Coleman, Michael P ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; TAU PROTEIN; APOLIPOPROTEIN E4; MAPT PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; MUTATION; NERVE FIBER; NEURITE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MOUSE; NERVE FIBER TRANSPORT; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEIN E4; AXONAL TRANSPORT; AXONS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MODELS, BIOLOGICAL; TAU PROTEINS;

EID: 34047181415     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.02.004     Document Type: Article

References (81)

1. Hardy J. A hundred years of Alzheimer's disease research. Neuron 52 (2006) 3-13
2. Spillantini M.G., et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7737-7741
3. Hutton M., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998) 702-705
4. Strittmatter W.J., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 1977-1981
5. Lewis J., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
6. Oddo S., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 (2003) 409-421
7. Tsai J., et al. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 7 (2004) 1181-1183
8. Tesseur I., et al. Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am. J. Pathol. 157 (2000) 1495-1510
9. Spittaels K., et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 155 (1999) 2153-2165
10. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
11. Stokin G.B., et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307 (2005) 1282-1288
12. Maloney M.T., et al. Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid β: a feedforward mechanism for Alzheimer's disease. J. Neurosci. 25 (2005) 11313-11321
13. Mandelkow E.M., et al. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24 (2003) 1079-1085
14. Mahley R.W., et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5644-5651
15. Brendza R.P., et al. PDAPP; YFP double transgenic mice: a tool to study amyloid-β associated changes in axonal, dendritic, and synaptic structures. J. Comp. Neurol. 456 (2003) 375-383
16. Spires T.L., et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25 (2005) 7278-7287
17. Lazarov O., et al. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J. Neurosci. 22 (2002) 9785-9793
18. Sheng J.G., et al. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Aβ amyloidosis. J. Neurosci. 22 (2002) 9794-9799
19. Muresan Z., and Muresan V. Neuritic deposits of amyloid-β peptide in a subpopulation of central nervous system-derived neuronal cells. Mol. Cell. Biol. 26 (2006) 4982-4997
20. Lee E.B., et al. BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo. J. Cell Biol. 168 (2005) 291-302
21. Lazarov O., et al. Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J. Neurosci. 25 (2005) 2386-2395
22. Cirrito J.R., et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48 (2005) 913-922
23. Qiu Z., et al. A novel approach for studying endogenous aβ processing using cultured primary neurons isolated from APP transgenic mice. Exp. Neurol. 170 (2001) 186-194
24. Wirths, O. et al. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2006.07.021
25. Suo, Z. et al. GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2006.08.013
26. Song M.S., et al. Apoptosis is secondary to non-apoptotic axonal degeneration in neurons exposed to Aβ in distal axons. Neurobiol. Aging 27 (2005) 1224-1238
27. Wirths O., et al. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol. (Berl.) 111 (2006) 312-319
28. Park J.H., et al. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-β plaque deposition. J. Neurosci. 26 (2006) 1386-1395
29. Phinney A.L., et al. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J. Neurosci. 19 (1999) 8552-8559
30. Hiruma H., et al. Glutamate and amyloid β-protein rapidly inhibit fast axonal transport in cultured rat hippocampal neurons by different mechanisms. J. Neurosci. 23 (2003) 8967-8977
31. Takahashi R.H., et al. Oligomerization of Alzheimer's β-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24 (2004) 3592-3599
32. Gunawardena S., and Goldstein L.S. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32 (2001) 389-401
33. Salehi A., et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51 (2006) 29-42
34. Ishihara T., et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24 (1999) 751-762
35. Lewis J., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25 (2000) 402-405
36. Probst A., et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. (Berl.) 99 (2000) 469-481
37. Gotz J., et al. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276 (2001) 529-534
38. Terwel D., et al. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J. Biol. Chem. 280 (2005) 3963-3973
39. Santacruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
40. Chee F.C., et al. Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol. Dis. 20 (2005) 918-928
41. Mudher A., et al. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry 9 (2004) 522-530
42. Kraemer B.C., et al. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9980-9985
43. Seitz A., et al. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J. 21 (2002) 4896-4905
44. Stamer K., et al. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156 (2002) 1051-1063
45. Mandelkow E.M., et al. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J. Cell Biol. 167 (2004) 99-110
46. Spittaels K., et al. Glycogen synthase kinase-3β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275 (2000) 41340-41349
47. Nuydens R., et al. Coexpression of GSK-3β corrects phenotypic aberrations of dorsal root ganglion cells, cultured from adult transgenic mice overexpressing human protein tau. Neurobiol. Dis. 9 (2002) 38-48
48. Lee V.M., et al. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
49. Zhang B., et al. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 24 (2004) 4657-4667
50. Utton M.A., et al. The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. J. Neurosci. 22 (2002) 6394-6400
51. Ignatius M.J., et al. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 1125-1129
52. Xu Q., et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26 (2006) 4985-4994
53. Vance J.E., et al. Lipid dynamics in neurons. Biochem. Soc. Trans. 34 (2006) 399-403
54. Harris F.M., et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10966-10971
55. Buttini M., et al. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation. J. Neurosci. 22 (2002) 10539-10548
56. -/- mice: isoform-specific effects on neurodegeneration. J. Neurosci. 19 (1999) 4867-4880
57. Wang C., et al. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol. Dis. 18 (2005) 390-398
58. Hering H., et al. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 23 (2003) 3262-3271
59. Klopfenstein D.R., et al. Role of phosphatidylinositol(4,5)bisphosphate organization in membrane transport by the Unc104 kinesin motor. Cell 109 (2002) 347-358
60. Conforti L., et al. Neuronal death: where does the end begin?. Trends Neurosci. 30 (2007) 159-166
61. Busciglio J., et al. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14 (1995) 879-888
62. Zheng W.H., et al. Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 115 (2002) 201-211
63. Ferrari A., et al. β-Amyloid induces paired helical filament-like tau filaments in tissue culture. J. Biol. Chem. 278 (2003) 40162-40168
64. Gotz J., et al. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ 42 fibrils. Science 293 (2001) 1491-1495
65. Rapoport M., et al. Tau is essential to β-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6364-6369
66. King M.E., et al. Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid. J. Cell Biol. 175 (2006) 541-546
67. Oddo S., et al. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J. Biol. Chem. 281 (2006) 1599-1604
68. Goldsbury C., et al. Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-β peptides. Traffic 7 (2006) 873-888
69. Minamide L.S., et al. Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Nat. Cell Biol. 2 (2000) 628-636
70. Fulga T.A., et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat. Cell Biol. 9 (2007) 139-148
71. Holtzman D.M., et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2892-2897
72. Grimm M.O., et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat. Cell Biol. 7 (2005) 1118-1123
73. Ehehalt R., et al. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
74. Ye S., et al. Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18700-18705
75. Gylys K.H., et al. Increased cholesterol in Aβ-positive nerve terminals from Alzheimer's disease cortex. Neurobiol. Aging. 28 (2007) 8-17
76. Andersen O.M., and Willnow T.E. Lipoprotein receptors in Alzheimer's disease. Trends Neurosci. 29 (2006) 687-694
77. Brecht W.J., et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24 (2004) 2527-2534
78. Tesseur I., et al. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am. J. Pathol. 156 (2000) 951-964
79. Genis I., et al. Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci. Lett. 199 (1995) 5-8
80. Glynn P. A mechanism for organophosphate-induced delayed neuropathy. Toxicol. Lett. 162 (2006) 94-97
81. Misgeld T., and Kerschensteiner M. In vivo imaging of the diseased nervous system. Nat. Rev. Neurosci. 7 (2006) 449-463